Treatments for Ebola Virus Disease
- Name
- Treatments for Ebola Virus Disease
- Accession Number
- DBCAT005186
- Description
Not Available
- Drugs
Drug Drug Description Maftivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Atoltivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Odesivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Ansuvimab A fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. - Drugs & Drug Targets
Drug Target Type Maftivimab Envelope glycoprotein target Atoltivimab Envelope glycoprotein target Odesivimab Envelope glycoprotein target Ansuvimab Envelope glycoprotein target